|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.09 USD | -36.07% |
|
-44.41% | -46.91% |
| 12-05 | Top Premarket Decliners | MT |
| 11-11 | Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | CI |
Company Valuation: Quoin Pharmaceuticals, Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15.19 | 6.883 | 4.842 | 5.328 | 10.14 | - | - |
| Change | - | -54.69% | -29.65% | 10.02% | 90.39% | - | - |
| Enterprise Value (EV) | 15.19 | 6.883 | 4.842 | 5.328 | 10.14 | 10.14 | 10.14 |
| Change | - | -54.69% | -29.65% | 10.02% | 90.39% | 0% | 0% |
| P/E ratio | -0.34x | -0.36x | -0.51x | -0.34x | -0.6x | -1.75x | -23.3x |
| PBR | - | - | - | - | - | - | - |
| PEG | -0x | 0x | 0x | 0x | 0x | 0x | 0.3x |
| Capitalization / Revenue | - | - | - | - | - | - | 0.27x |
| EV / Revenue | - | - | - | - | - | - | 0.27x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0.64x | -0.49x | 1.2x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -28,455 | -1,638 | -337.4 | -66.85 | -20.16 | -6.91 | -0.52 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 37.47 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -6.063 | -9.258 | -9.378 | -9.528 | -15.8 | -20.79 | 8.426 |
| Net income 1 | -21.46 | -9.447 | -8.687 | -8.962 | -15.44 | -17.9 | -1.351 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 9,555.01 | 596.40 | 171.68 | 22.77 | 12.09 | 12.09 | 12.09 |
| Nbr of stocks (in thousands) | 1.59 | 11.5 | 28.2 | 234 | 839 | - | - |
| Announcement Date | 14/04/22 | 09/03/23 | 13/03/24 | 13/03/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.6x | - | - | - | 10.14M | |
| 37.75x | 5.5x | 18.58x | 0.92% | 47.37B | |
| 31.8x | 3.2x | 13.81x | -.--% | 38.46B | |
| 103.74x | 6.32x | 63.39x | -.--% | 35.73B | |
| 51.48x | 9.93x | 28.1x | 0.4% | 27.23B | |
| 37.03x | 5.99x | 27.2x | -.--% | 15.44B | |
| -14.27x | 5565.23x | -13.44x | -.--% | 15.4B | |
| 28.78x | 2.13x | 10.9x | -.--% | 14.19B | |
| -51.58x | 11.12x | 28622.4x | -.--% | 13.64B | |
| -36.27x | 13.75x | -39.24x | -.--% | 13.23B | |
| Average | 18.78x | 624.80x | 3,192.41x | 0.15% | 22.07B | |
| Weighted average by Cap. | 34.87x | 394.29x | 1,788.24x | 0.25% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- QNRX Stock
- Valuation Quoin Pharmaceuticals, Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition